Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.14M P/E - EPS this Y 50.40% Ern Qtrly Grth -
Income -25.17M Forward P/E -0.64 EPS next Y 21.50% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -33.00%
Dividend N/A Price/Book 0.42 EPS next 5Y - 52W High Chg -65.00%
Recommedations 2.00 Quick Ratio 1.89 Shares Outstanding 2.84M 52W Low Chg 25.00%
Insider Own 3.53% ROA -47.68% Shares Float 2.33M Beta 1.85
Inst Own 11.11% ROE -86.82% Shares Shorted/Prior 125.22K/51.33K Price 0.65
Gross Margin - Profit Margin - Avg. Volume 187,970 Target Price 31.67
Oper. Margin - Earnings Date Nov 11 Volume 23,068 Change 0.78%
About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech, Inc. News
11/18/24 New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
11/14/24 Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
11/12/24 Moleculin Biotech Reports Financial Highlights and Future Plans
11/12/24 Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
11/11/24 Q3 2024 Moleculin Biotech Inc Earnings Call
11/11/24 Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/05/24 Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
11/04/24 Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
10/18/24 Moleculin Biotech Highlights Annamycin’s AML Treatment Potential
10/17/24 Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
10/09/24 Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
10/07/24 Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
10/04/24 Moleculin to Present at Two Upcoming Investor Conferences
09/23/24 Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
09/16/24 Moleculin Participates in Virtual Investor "What this Means" Segment
09/09/24 Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
09/03/24 Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/26/24 Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
08/19/24 Moleculin Announces Closing of up to $16.5 Million Public Offering
08/16/24 Moleculin Announces Pricing of up to $16.5 Million Public Offering
MBRX Chatroom

User Image sprinx Posted - 6 hours ago

$MBRX I smell something brewing here. Like buyout or partnership…….its smells good;)

User Image jkgyuool Posted - 18 hours ago

$MBRX 👇🏽👇🏽👇🏽next move? Everyone knows what happens when the mouse opens his mouth. Desperation

User Image cheeseandsmile Posted - 1 day ago

$MBRX " ... Guys, Don't miss the next move in a few hours ..." Pathetic bots!!!

User Image Shootingstar27 Posted - 1 day ago

$MBRX all the gain will vanish once the market opens😂😂

User Image shmewski Posted - 1 day ago

$MBRX IP has to be sold.

User Image Cancercrusader Posted - 2 days ago

$MBRX For anyone who hasn’t followed this company for a while they are fantastic at spending money on trials that’s do nothing, go nowhere and reverse splits. Take whatever money you haven’t lost yet and buy $IBRX

User Image Paperpino Posted - 2 days ago

$MBRX

User Image Tjdaz Posted - 2 days ago

$MBRX whenever the news is good the price drops ????

User Image jkgyuool Posted - 3 days ago

$MBRX I read that Venetoclax made by Abbvie revenued 2.3B 2023. Is this true? Also why this PR today to compare Venetoclax. I’m hoping for big partner soon. Hopefully takes more dilution off table

User Image sprinx Posted - 3 days ago

$MBRX

User Image The_Pubic_Defender Posted - 4 days ago

$ZONE When you look at stocks like $CYTO and $MBRX that have recent offerings - with WAINRIGHT, no less - you naturally appreciate the stability of a stock like $ZONE running on good earnings.

User Image cheeseandsmile Posted - 6 days ago

$MBRX

User Image ezMoney001 Posted - 6 days ago

$MBRX Wow that was unexpected l😂. - ez + ez -

User Image Specims Posted - 6 days ago

$MBRX rug pull

User Image bilskybill2 Posted - 6 days ago

$MBRX This stock will be OK when Trump takes over in January because they know how Big Pharma controls everything related to health.

User Image cheeseandsmile Posted - 6 days ago

$MBRX Warrants-Holder are done but hey $MBRX got some cash👏

User Image jkgyuool Posted - 6 days ago

$MBRX we need less rodents in this world!

User Image jkgyuool Posted - 6 days ago

$MBRX Mouse favorite words is 👀 and learn! Only comes out when news about to come out and starts to bash the SP instead of criticizing what’s truly going on. Acts like he works for hedge company crooks

User Image cheeseandsmile Posted - 6 days ago

$MBRX 👀 & learn chief of trolls

User Image bilskybill Posted - 6 days ago

$MBRX Looks like we attracted more short sellers again. Way to go losers.

User Image Davidwxyz Posted - 6 days ago

$MBRX bought some at 2.93.

User Image jkgyuool Posted - 6 days ago

$MBRX 👇🏽👇🏽👇🏽👇🏽everyone welcome our Grade A Troll Mr mouse!! Only comes out strategically

User Image cheeseandsmile Posted - 6 days ago

$MBRX Armistice Capital, LLC Share VP 3,316,221 at 12/31/2023 (9.99%) | SC 13G/A Armistice Capital, LLC Share VP 300,988 at 09/30/2024 (9.99%) - Find the mistake lol

User Image DjStockTrades Posted - 6 days ago

WL for 11/15/24: 👀 $SYTA $IBG $ADGM $MBRX $AREN

User Image TheRealShortSqueezy Posted - 1 week ago

$IBG 1.80$ is next... 150k+ short share to return !!! Going to be a sick squeeze !! $ENSC $XPON $PULM $MBRX They all joining the game. Top runners are sick today!

User Image jkgyuool Posted - 1 week ago

$MBRX 👇🏽👇🏽👇🏽desperate mouse

User Image cheeseandsmile Posted - 1 week ago

$MBRX here we go ⬇️

User Image cheeseandsmile Posted - 1 week ago

$MBRX back to 2.50

User Image jkgyuool Posted - 1 week ago

$MBRX Wow look how active the mouse is today!!! Unbelievably vocal!! No wonder price 🚀

User Image Bornjever Posted - 1 week ago

$MBRX yes Yahoo has 4 analysts on this and all strong buy. It cannot be better than this. Glad I looked before sold it all.

Analyst Ratings
Roth MKM Buy Apr 12, 24
Maxim Group Buy Mar 26, 24
HC Wainwright & Co. Buy Dec 14, 23
Roth MKM Buy Apr 18, 23
Oppenheimer Outperform Mar 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Foster Jonathan P. Chief Financial Offi.. Chief Financial Officer Dec 26 Buy 0.69 28,986 20,000 80,556 12/27/23
George Robert E. Director Director Dec 26 Buy 0.69 14,493 10,000 14,660 12/27/23
KLEMP WALTER V CEO and President CEO and President Dec 26 Buy 0.69 188,404 129,999 680,880 12/27/23
KLEMP WALTER V CEO and President CEO and President Nov 25 Buy 1.2807 45,000 57,632 409,890 11/28/22
KLEMP WALTER V CEO and President CEO and President Nov 21 Buy 1.1496 22,500 25,866 364,890 11/23/22
KLEMP WALTER V CEO and President CEO and President Nov 16 Buy 1 109,955 109,955 342,390 11/18/22